Short answer
Your professional corporation can never be qualified small business stock, because Section 1202(e)(3) excludes businesses performing services in the field of health. The open question is the management company holding stock you receive as rollover. It is genuinely unsettled, and there is no IRS ruling. But the field of health debate is usually not what decides it. Three other requirements come first: the entity has to be a C corporation, and a great many rollover vehicles are LLCs or partnerships that cannot issue QSBS at all; the corporation's gross assets cannot exceed $75 million at the time your stock is issued, and a private equity platform that has already bought several practices is frequently past that line; and you need a five-year holding period, which rarely matches a sponsor's exit timeline. Treat any QSBS benefit on rollover stock as something you might discover later, never as a reason to accept a lower price or a different structure.
Key facts
- Your professional corporation
- Never QSBS. Section 1202(e)(3) excludes services in the field of health, with no exception and no gray area.
- The first gate: entity type
- QSBS is stock in a C corporation. If you roll into an LLC or partnership, the question ends there.
- The second gate: $75 million gross assets
- The corporation's aggregate gross assets cannot exceed $75 million at the time the stock is issued. An established platform often already exceeds this.
- The third gate: holding period
- Stock issued after July 4, 2025 needs 3 years for a 50% exclusion, 4 for 75%, and 5 for 100%. Sponsors often exit before five years.
- The debated gate: field of health
- Whether a management company serving medical practices is itself in the field of health has no IRS ruling. Unsettled means unsettled.
- California
- Does not conform to Section 1202 at all, so a California resident owes state tax on the full gain regardless.
The part that is not debatable
Your professional corporation cannot issue qualified small business stock, and no structure or holding period changes that. Section 1202(e)(3) excludes any trade or business performing services in the field of health, and it sits on the same list as law, accounting, consulting, financial services, and brokerage. A practice that delivers medical or dental care is inside the exclusion. If an advisor suggests otherwise about the PC itself, that is not a close call, and the QSBS page covers the basic rules.
What is left is a narrower and more interesting question. In a friendly PC and management company structure, you usually receive rollover equity in the holding company above the MSO rather than in the practice. That entity does not treat patients. So can its stock be QSBS?
The argument on both sides
The case for it is that the management company is a genuinely different business. The licensed professional corporation employs the physicians and delivers the care. The management company runs billing, scheduling, human resources, purchasing, real estate, and technology, and sells those services under a management agreement. Read that way, it provides administrative services, not health services, and it is not obviously inside the statutory exclusion. The MSO and friendly PC page explains why the two entities are separated in the first place.
The case against it is that the entire enterprise exists to serve medical practices, its revenue is a share of what those practices collect, and its value is the value of the clinical operations it manages. A court asked whether that is a business performing services in the field of health could reasonably say yes. The IRS has not ruled, there is no published guidance directly on point, and reasonable advisors disagree.
Unsettled means unsettled. Anyone who tells you this question has a clear answer is telling you something the law does not currently support, in either direction.
Three tests that usually decide it first
In most real transactions the field of health debate never gets reached, because the deal fails one of three plainer requirements. These are worth checking before anyone spends an hour arguing about the statute.
The first is the entity itself. QSBS is stock in a C corporation. A large share of rollover vehicles in these deals are limited liability companies or limited partnerships, and those cannot issue qualified small business stock at all. This is answered by reading the rollover documents, it takes a few minutes, and it ends the analysis more often than any other factor.
The second is the size of the company when your stock is issued. The corporation's aggregate gross assets cannot exceed $75 million at the time of issuance. A platform that has already rolled up several practices, or that carries acquisition goodwill and debt on its balance sheet, is frequently well beyond that line by the time you join. The test looks at the company when your shares are issued, so being early in a platform's life matters enormously and being the fifteenth practice acquired usually settles it.
The third is time. For stock issued after July 4, 2025, the exclusion arrives in tiers: 50 percent of the gain at three years, 75 percent at four years, and 100 percent at five. Sponsors generally aim to exit somewhere between three and six years, and you do not control when. A sale at year four produces a partial exclusion, and the portion that is not excluded in the three and four year tiers is taxed at 28 percent rather than the usual 20 percent. Even the good version of this outcome is worth less than the pitch implies.
What this means in a negotiation
Treat a possible QSBS benefit on rollover stock as a lottery ticket that costs nothing, and refuse to pay anything for it. That means not accepting a lower headline price because of it, not agreeing to a larger rollover than you otherwise want, not conceding on the purchase price allocation, and not choosing a C corporation structure you would not choose for its own reasons.
If a banker or the buyer raises it, three questions settle whether it deserves any weight at all. Is the rollover vehicle a C corporation? What are the entity's aggregate gross assets at the moment my stock is issued? What hold period does the sponsor expect? If any answer is unfavorable, the statutory debate is beside the point and the item should not move a single term. If all three come back favorable, then it is worth getting a written opinion and worth structuring carefully, and it is still not worth giving up price.
One more thing that applies regardless. California does not conform to Section 1202, so a California resident owes state tax on the entire gain even in the version of this where the federal exclusion works perfectly. The California page covers the state's other departures from federal law.
Where to spend the effort instead
The reason to be blunt about this is that the certain items are worth more than the uncertain one. The allocation between goodwill and the non-compete is worth roughly $170,000 of federal tax per million dollars moved, and it is negotiable. A final-year cash balance plan is a large deduction with no legal uncertainty at all. The rollover terms and the waterfall determine whether the second payment exists. Each of those is knowable now.
The full tax strategy list puts every lever in order of when it has to happen. If you want someone to read your rollover documents and tell you which of the three gates above your deal actually clears, that is a term-sheet review.
Questions people ask
Why can my professional corporation never be QSBS?
Section 1202(e)(3) lists the businesses that cannot issue qualified small business stock, and any trade or business performing services in the field of health is on that list, alongside law, accounting, actuarial science, performing arts, athletics, consulting, financial services, and brokerage. A professional corporation that practices medicine or dentistry is squarely inside the exclusion. How the entity is taxed, how long you held it, and how profitable it is make no difference.
So what is the MSO argument?
That the management company is a different business from the practice. In a friendly PC structure the licensed professional corporation employs the physicians and delivers the care, while the management company provides billing, scheduling, human resources, real estate, purchasing, and technology. On that reading the management company sells administrative services rather than health services, and it is not obviously inside the exclusion. The counter-argument is that its entire business exists to serve medical practices and derives its value from them, and that a court could read the field of health broadly enough to capture it. The IRS has not ruled either way.
Which requirement usually kills it first?
The gross asset test, followed closely by the entity type. The corporation's aggregate gross assets must not exceed $75 million at the time your stock is issued. A platform that has already acquired a handful of practices, or that is carrying acquisition debt and goodwill on its balance sheet, is frequently well past that. And a large share of rollover vehicles are LLCs or limited partnerships rather than C corporations, which ends the analysis before it starts. Read the rollover documents for the entity type first. It takes a minute and it answers the question most of the time.
Does the five-year holding period realistically work?
Often it does not. For stock issued after July 4, 2025, the exclusion is tiered: 50 percent of the gain at three years, 75 percent at four, and 100 percent at five. Sponsors typically target an exit in three to six years, and you do not control the timing. A second bite at year four would deliver a partial exclusion at best, and the taxable slice in the three and four year tiers is taxed at 28 percent rather than the usual 20 percent. So even the favorable version is less valuable than the headline suggests.
Should I pay anything for this possibility?
No, and this is the practical point of the page. Do not accept a lower headline price, a larger rollover, a worse allocation, or a C corporation structure you would not otherwise want because someone has raised the possibility of QSBS on the rollover. You would be paying certain money for an uncertain benefit that at least three other tests can independently defeat. If it turns out to be available years later, treat it as a windfall your return preparer identifies at the time.
What if a banker or the buyer raises QSBS as a selling point?
Ask three questions in order. Is the rollover vehicle a C corporation? What were the entity's aggregate gross assets at the time my stock is issued? And what is the expected hold period? If any of those answers is unfavorable, the field of health debate is irrelevant and the point should carry no weight in the negotiation. If all three are favorable, it is worth a written opinion, and it is still not worth conceding price over.